Since the phenomenon of GV is more pronounced in patients with T1DM compared to type 2 diabetes mellitus (T2DM) patients, as individuals with T1DM do not benefit from the stabilizing effect provided by residual insulin secretion [38], the clinical impact of GV is emphasized in patients with T1DM. This evidence concerns the gene INS and type 2 diabetes mellitus.